The French version of the FDA gave approval today to start a confirmatory phase 3 study of Masitinib for MS.
J
Anyone has any idea when updates on Covid trial are expected, if any?
C
"Scientists from the University of Chicago have found that the drug masitinib may be effective in treating COVID-19."
"Now, the team is working with the pharmaceutical company that developed masitinib (AB Science) to tweak the drug to make it an even more effective antiviral. Meanwhile, masitinib itself could be taken to human clinical trials in the future to test it as a COVID-19 treatment."
Listened to the CC, which was disorganized. Nonetheless, I think there really is something here. There is a mechanism of action which is plausible and unique, and the statistical significance is impressive. It is also heartening that there is some efficacy in MS and ALS. I didn't recognize any analysts asking questions, which is unfortunate. The market cap is truly tiny comparing it to so many biotechs with less editing prospects.
g
AB SCIENCE ANNOUNCES THE SUCCES OF ITS CAPITAL RAISE FOR A TOTAL AMOUNT OF 15.0 MILLION EUROS
·10.5 million euros raised through a private placement and accelerated book-building procedure, without discount, at a price of 14.42 euros per ordinary share.
·This private placement triggers the conversion of the convertible bonds announced on October 29, 2020 with a nominal value of 4.5 million euros.
Paris, France – December 21, 2020 AB Science (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces a capital raise of 10.5 million euros by way of issuance of 728,156 new ordinary shares (the “New Shares”). The capital raise was subscribed by European and north American qualified investors (the “Capital Raise”).
G
so this will just quietly double in short order?
s
Who is here? Anyone?
A
Unusual that it didn’t spike with Masitinib presentation at ats.
s
Anyone here ?
R
Why no trading after 12:50 today? Is this stock halted until after the meeting tomorrow? Very strange going on here.
"Now, the team is working with the pharmaceutical company that developed masitinib (AB Science) to tweak the drug to make it an even more effective antiviral. Meanwhile, masitinib itself could be taken to human clinical trials in the future to test it as a COVID-19 treatment."
https://www.news-medical.net/news/20210802/Existing-drug-may-be-effective-in-treating-SARS-CoV-2.aspx
I didn't recognize any analysts asking questions, which is unfortunate. The market cap is truly tiny comparing it to so many biotechs with less editing prospects.
·10.5 million euros raised through a private placement and accelerated book-building procedure, without discount, at a price of 14.42 euros per ordinary share.
·This private placement triggers the conversion of the convertible bonds announced on October 29, 2020 with a nominal value of 4.5 million euros.
Paris, France – December 21, 2020
AB Science (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces a capital raise of 10.5 million euros by way of issuance of 728,156 new ordinary shares (the “New Shares”). The capital raise was subscribed by European and north American qualified investors (the “Capital Raise”).